Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Gross Margin (2016 - 2025)

Historic Gross Margin for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to 87.38%.

  • United Therapeutics' Gross Margin fell 15200.0% to 87.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 116.47%, marking a year-over-year increase of 306900.0%. This contributed to the annual value of 89.24% for FY2024, which is 3000.0% up from last year.
  • Latest data reveals that United Therapeutics reported Gross Margin of 87.38% as of Q3 2025, which was down 15200.0% from 89.03% recorded in Q2 2025.
  • Over the past 5 years, United Therapeutics' Gross Margin peaked at 94.39% during Q1 2022, and registered a low of 7000.0% during Q4 2023.
  • Its 5-year average for Gross Margin is 303.37%, with a median of 89.25% in 2023.
  • In the last 5 years, United Therapeutics' Gross Margin surged by 19700bps in 2022 and then plummeted by -70880400bps in 2023.
  • Over the past 5 years, United Therapeutics' Gross Margin (Quarter) stood at 91.67% in 2021, then dropped by -4bps to 88.04% in 2022, then crashed by -8051bps to 7000.0% in 2023, then skyrocketed by 101bps to 88.9% in 2024, then dropped by -2bps to 87.38% in 2025.
  • Its last three reported values are 87.38% in Q3 2025, 89.03% for Q2 2025, and 88.36% during Q1 2025.